Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Financing led by a16z and Deerfield Management with participation from Droia Ventures, GV, The Mark Foundation for Cancer Research and the Berkeley Catalyst Fund Exclusive license from academic-industry collaboration with UC Berkeley Professor Daniel Nomura for proprietary DUBTAC platform for targeted protein stabilization SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Vicinitas Therapeutics, a biotechnology company advancing a … Read more